Search

Germany: Potential Cure for Coronavirus Biontech, Pfizer Reveal Further Details on Collaboration to Develop Covid-19 Vaccine

| Editor: Ahlam Rais

Biontech and Pfizer’s collaboration aims to rapidly develop the Covid-19 vaccine in order to support the global supply. By the end of this year, the company has the capability to supply millions of vaccine doses subject to technical success of the development programme and approval by regulatory authorities.

Related Companies

During the clinical development stage, Biontech and its partners will provide clinical supply of the vaccine from its GMP-certified Mrna manufacturing facilities in Europe.
During the clinical development stage, Biontech and its partners will provide clinical supply of the vaccine from its GMP-certified Mrna manufacturing facilities in Europe.
(Source: Deposit Photos)

Mainz/Germany – Biontech and Pfizer have recently disclosed additional details of their collaboration to advance candidates from Biontech’s Mrna vaccine programme, previously announced on March 17, 2020.

The collaboration aims to rapidly advance multiple covid-19 vaccine candidates into human clinical testing based on Biontech’s proprietary Mrna vaccine platforms, with the objective of ensuring rapid worldwide access to the vaccine, if approved. The collaboration will leverage Pfizer’s broad expertise in vaccine research and development, regulatory capabilities, and global manufacturing and distribution network.

The two companies plan to jointly conduct clinical trials for the Covid-19 vaccine candidates initially in the United States and Europe across multiple sites. Biontech and Pfizer intend to initiate the first clinical trials as early as the end of April 2020, assuming regulatory clearance.

During the clinical development stage, Biontech and its partners will provide clinical supply of the vaccine from its GMP-certified Mrna manufacturing facilities in Europe. Biontech and Pfizer will work together to scale-up manufacturing capacity at risk to provide worldwide supply in response to the pandemic. Biontech and Pfizer will also work jointly to commercialise the vaccine worldwide (excluding China, which is already covered by Biontech’s collaboration with Fosun Pharma) upon regulatory approval.

Specialist Book „Heat Transfer Technique“The comprehensive standard work „Heat Transfer Technique“ offers not only a detailed and well-founded presentation of the basics of heat transfer technique, but also shows the latest state of the art and the latest regulations in the use of organic fluids. Thematically, the book is rounded off with an overview of property data of organic heat transfer fluids as well as many use cases from practical experience.

“Combatting the Covid-19 pandemic will require unprecedented collaboration across the innovation ecosystem, with companies coming together to unite capabilities like never before,” said Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development & Medical, Pfizer. “I am proud of Pfizer’s collaboration with Biontech and have every confidence in our ability to harness the power of science – together – to bring forth a potential vaccine that the world needs as quickly as possible.”

“We have already started working with Pfizer on our Covid-19 vaccine and are pleased to announce these further details of our ongoing collaboration, which reflects both companies’ strong commitment to move quickly to bring a safe and efficacious vaccine to patients worldwide,” says Co-Founder and CEO of Biontech, Ugur Sahin, M.D.

Under the terms of the agreement, Pfizer will pay Biontech 185 million dollars in upfront payments, including a cash payment of 72 million dollars and an equity investment of 113 million dollars. Biontech is eligible to receive future milestone payments of up to 563 million dollars for a potential total consideration of 748 million dollars. Pfizer and Biontech will share development costs equally. Initially, Pfizer will fund 100 per cent of the development costs, and Biontech will repay Pfizer its 50 per cent share of these costs during the commercialisation of the vaccine.

(ID:46508548)